GuruFocus Updates (Free subscription) | yesterday
By guruyt. Last week's top five stocks that reached their 52-week lows were Genzyme Corp, Apollo Group Inc, Cogent Inc, AMERICAN PUBLIC EDUCATION, INC, and Whitney Holding Corp. According to GuruFocus updates, these Guru stocks have reached their 52-week lows. Read more » »
The IN VIVO Blog (Free subscription) | 20/11/2009
People, we seriously need to talk about Eggo Waffles. But first, a dearth of meaty deals this week has us thinking more about Bristol-Myers Squibb's share-swap/buyback/spin-off of its nutritionals unit Mead Johnson. We tried to make the point earlier this week that Bristol's move was too focused on short-term gain. Others have pointed out to us that without some sort of short-term gain to appease...
10Q Detective (Free subscription) | 20/11/2009
Genzyme (GENZ-$49.63) has already spent more than $1 billion in the last two years to build new and bigger bioreactors — notably in the U.S., Ireland, and Belgium. Eventual plans call for total perfusion bioreactor capacity to climb from 20,000 Liters to 32,000 Liters by 2012. The global brewer of enzyme replacement therapies for rare genetic diseases disclosed this week that the FDA was delaying...
Medical News Today (Free subscription) | 20/11/2009
Genzyme Corporation (Nasdaq: GENZ) reported results of a phase 2/3 study of its advanced phosphate binder (APB). The trial met its primary endpoint, which was to show that the APB lowered phosphate levels effectively compared to placebo. However, the APB did not show a significant improvement in phosphate lowering compared to Genzyme's Renvela® (sevelamer carbonate). Based on these results, the...
Fool.com (Free subscription) | 19/11/2009
Genzyme's string of missteps has investors nervous.
The Street (Free subscription) | 19/11/2009
See who made what calls.
Xconomy (Free subscription) | 19/11/2009
Believe it or not, the troubles besetting Genzyme (NASDAQ: GENZ) were not the only life science stories coming out of the Boston area this week, although they sure grabbed most of the attention. So let’s get them all out of the way first: —On Friday the 13th, the FDA said bits of steel, rubber, and fiber [...]
Uremic Frost (Free subscription) | 18/11/2009
Well, I just had the "delicious" powder form of Renvela today. The citrusy taste isnt too bad, but I still feel the particles in the back of my throat. I am curious to see what dialyzors think about this new form of Renvela. My Genzyme rep has been quick to point to the problems with the unconventional Fosrenol, but now he seems to believe this will be a hit. I am skeptical. One thing my...
Health Care Renewal (Free subscription) | 18/11/2009
In June, 2009, an article in the Boston Globe described how the Boston area based biotechnology company Genzyme sold some astonishlingly expensive drugs, using a remarkable business strategy : In countries from Colombia to Taiwan to Libya, the Cambridge firm has compiled an extraordinary track record of searching out patients like Tania, providing desperately needed treatment, and then successfully...
Xconomy (Free subscription) | 18/11/2009
Another day, another piece of bad news from Genzyme. The Cambridge, MA-based biotech giant (NASDAQ: GENZ) said today it is scrapping development of a next-generation drug for kidney disease after it was unable to beat its existing treatment on the market. Genzyme’s experimental drug, called an advanced phosphate binder, didn’t appear any better at getting rid [...]
Contract Pharma Breaking News (Free subscription) | 18/11/2009
Genzyme Corp. reported results of a Phase II/III study of its advanced phosphate binder (APB). Although the trial met its primary endpoint, which was to show that the APB lowered phosphate levels compared to placebo, the APB did not show a significant improvement in phosphate lowering compared to Genzyme’s Renvela. As a result, the company is discontinuing further development of the drug. The...
The Street (Free subscription) | 18/11/2009
Company halts development of kidney disease drug following poor test results.
Business Wire (Free subscription) | 18/11/2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) today reported results of a phase 2/3 study of its advanced phosphate binder (APB). The trial met its primary endpoint, which was to show that the APB lowered phosphate levels effectively compared to placebo. However, the APB did not show a significant improvement in phosphate lowering compared to Genzyme’s Renvela® (sevelamer...
The IN VIVO Blog (Free subscription) | 18/11/2009
Friday's announcement that bits of rubber and other detritus were found in vials of five different drugs manufactured at Genzyme's beleaguered Allston Landing plant was worthy of the satirical publication " The Onion "--except that it was true. The picture grew murkier over the weekend, with the arrival of another Form 483 missive from FDA about ongoing manufacturing issues and a complete...
Xconomy (Free subscription) | 17/11/2009
The big new cholesterol-lowering drug from Genzyme and Isis Pharmaceuticals, which both companies are counting on as a future profit driver, passed its first major clinical trial, but investors didn’t like what they saw when full details were released this morning at a major medical meeting. Carlsbad, CA-based Isis Pharmaceuticals (NASDAQ: ISIS) fell 16 percent to [...]
Videos